# Late effects and survivorship toxicity

Source: https://onco.cc/terms/late-effects/  
OnCo record `late-effects` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Health problems appearing months or decades after treatment ends: heart damage, infertility, second cancers, lymphoedema, dry mouth, memory problems, weak bones. They matter most for children and young adults, who live longest with them.

## Summary

Two-thirds of childhood cancer survivors have at least one chronic condition by age 50 (Childhood Cancer Survivor Study), which is why paediatric oncology has spent decades reducing radiation and anthracycline doses without losing cure rates. Adult examples include lymphoedema (reduced by sentinel node biopsy), xerostomia and dysphagia after head and neck radiotherapy (reduced by IMRT), infertility (addressed by oncofertility and GnRH protection), premature menopause and osteoporosis from endocrine therapy, neuropathy, cardiomyopathy, and neurocognitive effects. Survivorship care plans, risk-based screening (breast MRI after chest radiotherapy, echocardiography after anthracyclines) and exercise programmes address them, and trials increasingly report late toxicity as a co-primary concern in de-escalation.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: late effects; late toxicity; late toxicities; long-term toxicity; long-term toxicities; long-term side effects; long-term effects; chronic toxicity; cumulative toxicity; cumulative dose; lifetime dose; infertility; gonadotoxicity; premature ovarian insufficiency; premature menopause; growth impairment; neurocognitive effects; neurocognitive decline; cognitive impairment; chemo brain; lymphoedema; lymphedema; xerostomia; dry mouth; osteoporosis; bone loss; osteonecrosis; osteonecrosis of the jaw; sexual dysfunction; childhood cancer survivors; childhood cancer survivor; cumulative doses

## Notes

- Bowel cancer: Bowel Cancer UK lists hernia at the wound or around the stoma (avoid heavy lifting for up to three months, then ask about core exercises and a support garment) and oxaliplatin neuropathy among the effects that last beyond six months or start later. NICE NG151 asks teams to give information about short-term, long-term, permanent and late side effects including pain, altered bowel, urinary or sexual function, nerve damage and neuropathy, and mental and emotional changes including anxiety, depression, chemotherapy-related cognitive impairment and changes to self-perception and social identity.
- Lymphoma: Lymphoma Action distinguishes late effects, which do not start until months or years after treatment finishes, from side effects that start during or soon after it, and says people treated for Hodgkin lymphoma have a slightly higher chance of late effects than people treated for non-Hodgkin lymphoma, with higher risk again for those treated in childhood or early adulthood. Its list covers the heart, second cancers, lung scarring, the thyroid, fertility, bone health, the eyes and the teeth, each tied to the treatment that causes it.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Late_effect
- Wikipedia: https://en.wikipedia.org/wiki/Late_effect
- Bowel Cancer UK: long term and late side effects: https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/long-term-and-late-side-effects/
- Macmillan: bowel changes after cancer treatment: https://www.macmillan.org.uk/cancer-information-and-support/bowel-cancer/managing-bowel-changes-after-treatment
- NICE NG151: colorectal cancer, recommendations: https://www.nice.org.uk/guidance/ng151/chapter/Recommendations
- Lymphoma Action: late effects of lymphoma treatment: https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment
- Schaapveld et al., second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, New England Journal of Medicine 2015 (3,905 Dutch survivors): https://doi.org/10.1056/NEJMoa1505949
- van Nimwegen et al., cardiovascular disease after Hodgkin lymphoma treatment, 40-year disease risk, JAMA Internal Medicine 2015 (2,524 Dutch patients): https://doi.org/10.1001/jamainternmed.2015.1180

## Connected records

- terms: [ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)](https://onco.cc/terms/abvd-beacopp/), [Adolescent and young adult (AYA) oncology](https://onco.cc/terms/aya-oncology/), [After Hodgkin lymphoma: the late effects, and the screening that follows them](https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/), [Age, smoking and inherited predisposition: what the treatment risk is added to](https://onco.cc/terms/rejuv-second-age-smoking-and-inherited-risk/), [Alkylating agents and therapy-related myeloid neoplasms](https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/), [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/), [Bladder cancer after cyclophosphamide](https://onco.cc/terms/second-primary-bladder-after-cyclophosphamide/), [Bowel cancer after abdominal and pelvic radiotherapy](https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/), [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [Choices made at the time of treatment that change the second cancer risk](https://onco.cc/terms/rejuv-second-choices-made-at-treatment/), [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Dysphagia (difficulty swallowing)](https://onco.cc/terms/dysphagia/), [Fatigue after lymphoma treatment, and why it is a symptom to report](https://onco.cc/terms/lymphoma-living-fatigue/), [Fertility preservation before lymphoma treatment: a decision with a deadline in days](https://onco.cc/terms/lymphoma-decision-fertility-timing/), [From a clone in the blood to a leukaemia: what is known, and what is done](https://onco.cc/terms/rejuv-second-from-clone-to-disease/), [Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them](https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/), [Low anterior resection syndrome (LARS)](https://onco.cc/terms/low-anterior-resection-syndrome/), [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Peripheral neuropathy (chemotherapy-induced)](https://onco.cc/terms/peripheral-neuropathy/), [Persistent chemotherapy-induced alopecia](https://onco.cc/terms/alopecia-persistent-chemotherapy/), [Persistent radiation-induced alopecia](https://onco.cc/terms/alopecia-radiotherapy-persistent/), [Platinum drugs and PARP inhibitors: the newer leukaemia risk](https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/), [Radiotherapy and second cancers: field, dose and age at exposure](https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/), [Sarcoma in the radiotherapy field, and angiosarcoma of the treated breast](https://onco.cc/terms/second-primary-sarcoma-in-the-treated-field/), [Screening survivors: where the UK, American and European answers differ](https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/), [Second cancers after treatment: what the risk is, and what is done about it](https://onco.cc/terms/rejuv-second-cancers-overview/), [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/), [Sexual function, fertility and body image after bowel cancer](https://onco.cc/terms/sex-fertility-after-bowel-cancer/), [Skin cancer after cancer treatment](https://onco.cc/terms/second-primary-skin-cancer-after-cancer-treatment/), [The scar on the face after skin cancer surgery](https://onco.cc/terms/facial-scar-after-skin-cancer/), [Thyroid cancer after neck radiotherapy, and whether to look for it](https://onco.cc/terms/second-primary-thyroid-after-neck-radiotherapy/), [Topoisomerase II inhibitors and the shorter latency](https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/)
- cancers: [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Atypical teratoid/rhabdoid tumour (ATRT)](https://onco.cc/cancers/atrt/), [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Central nervous system germ cell tumours (germinoma and non-germinomatous)](https://onco.cc/cancers/cns-germ-cell-tumours/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Ependymoma](https://onco.cc/cancers/ependymoma/), [Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)](https://onco.cc/cancers/malt-lymphoma/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Germ cell tumours of childhood and adolescence (extracranial and CNS)](https://onco.cc/cancers/paediatric-germ-cell-tumours/), [Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)](https://onco.cc/cancers/medulloblastoma-group-3-4/), [High-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-high-risk/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Intermediate-risk neuroblastoma](https://onco.cc/cancers/neuroblastoma-intermediate-risk/), [Langerhans cell histiocytosis (LCH)](https://onco.cc/cancers/langerhans-cell-histiocytosis/), [Low-risk neuroblastoma (INRG very low and low risk, including stage MS)](https://onco.cc/cancers/neuroblastoma-low-risk/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)](https://onco.cc/cancers/lch-multisystem/), [Nodal marginal zone lymphoma](https://onco.cc/cancers/nodal-marginal-zone-lymphoma/), [Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)](https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Paediatric high-grade glioma (excluding diffuse midline glioma)](https://onco.cc/cancers/paediatric-high-grade-glioma/), [Paediatric low-grade glioma](https://onco.cc/cancers/paediatric-low-grade-glioma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/), [Sezary syndrome](https://onco.cc/cancers/sezary-syndrome/), [SHH-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-shh/), [Single-system Langerhans cell histiocytosis (bone, skin or one other organ)](https://onco.cc/cancers/lch-single-system/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Splenic marginal zone lymphoma](https://onco.cc/cancers/splenic-marginal-zone-lymphoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/), [WNT-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-wnt/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [A changed face and voice: body image after head and neck cancer treatment](https://onco.cc/technologies/rejuv-mind-visible-difference-head-and-neck/), [Adolescents and young adults: a group with its own cancers, its own gap and its own needs](https://onco.cc/technologies/rejuv-ayac-distinct-group/), [After a transplant or cell therapy: what to ask for](https://onco.cc/technologies/rejuv-tx-what-to-ask-for/), [After treatment in Australia: a stated model of survivorship care](https://onco.cc/technologies/rejuv-access-survivorship-care-australia/), [After treatment in Germany: a rehabilitation entitlement, not a leaflet](https://onco.cc/technologies/rejuv-access-survivorship-care-germany/), [After treatment in low and middle income countries: mostly nothing](https://onco.cc/technologies/rejuv-access-survivorship-care-lmic/), [After treatment in the Nordic countries: rehabilitation written into the pathway](https://onco.cc/technologies/rejuv-access-survivorship-care-nordic/), [After treatment in the UK: personalised care, and follow-up you lead yourself](https://onco.cc/technologies/rejuv-access-survivorship-care-uk/), [After treatment in the United States: the survivorship care plan, and what the trial found](https://onco.cc/technologies/rejuv-access-survivorship-care-us/), [Anxiety after cancer, in survivors and in their partners](https://onco.cc/technologies/rejuv-mind-anxiety-after-cancer/), [B-cell aplasia and low antibodies after CAR-T and bispecifics, and immunoglobulin replacement](https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/), [Balance, dizziness and falls after cancer treatment](https://onco.cc/technologies/rejuv-rehab-balance-vestibular/), [Blood counts that do not come back after CAR-T: ICAHT](https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/), [Body image after cancer treatment: how it is measured, what drives it, and what helps](https://onco.cc/technologies/rejuv-mind-body-image-after-cancer/), [Bone after childhood cancer: peak bone mass, osteonecrosis and what rebuilds](https://onco.cc/technologies/rejuv-paed-bone/), [Bone loss caused by cancer treatment, and what rebuilds it](https://onco.cc/technologies/cancer-treatment-bone-loss/), [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [Bowel function after pelvic radiotherapy](https://onco.cc/technologies/bowel-after-pelvic-radiotherapy/), [Breast cancer after chest radiotherapy in childhood, and the screening that follows](https://onco.cc/technologies/rejuv-paed-breast-after-chest-radiotherapy/), [Breast reconstruction: implant and autologous, immediate and delayed, and what women report afterwards](https://onco.cc/technologies/rejuv-recon-breast/), [Breathing and exercise capacity after lung resection](https://onco.cc/technologies/rejuv-rehab-respiratory/), [Cancer rehabilitation: the discipline that puts function back](https://onco.cc/technologies/rejuv-rehab-cancer-rehabilitation/), [Cardiopulmonary exercise testing: the hardest number in recovery](https://onco.cc/technologies/rejuv-measure-cardiopulmonary-exercise-testing/), [Chronic graft-versus-host disease](https://onco.cc/technologies/gvhd-chronic-overview/), [Chronic GvHD organ by organ: skin, mouth, eyes, gut, liver, joints and genital tract](https://onco.cc/technologies/gvhd-organ-by-organ/), [Clonal haematopoiesis after cancer treatment](https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/), [Cognitive behavioural therapy for insomnia (CBT-I)](https://onco.cc/technologies/cbt-insomnia-cancer/), [Compounded hormone pellets](https://onco.cc/technologies/rejuv-frontier-hormone-pellets/), [Compression, decongestive therapy and exercise for lymphoedema](https://onco.cc/technologies/lymphoedema-decongestive-therapy/), [Depression during and after cancer: the interview-based prevalence, and the care model that works](https://onco.cc/technologies/rejuv-mind-depression-after-cancer/), [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/), [Education, work and the years that were interrupted](https://onco.cc/technologies/rejuv-ayac-education-and-work/), [Epigenetic age after cancer treatment](https://onco.cc/technologies/rejuv-age-epigenetic-clocks/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Exercise is the best-evidenced thing on this front, and most survivors are not doing it](https://onco.cc/technologies/rejuv-access-exercise-programmes/), [Fatigue after cancer treatment: what actually works](https://onco.cc/technologies/cancer-related-fatigue-management/), [Fear that the cancer will come back: how common it is, and when it stops being ordinary worry](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence/), [Fertility in boys and young men treated for cancer, including testicular tissue banking](https://onco.cc/technologies/rejuv-paed-fertility-male/), [Fertility in girls and young women treated for cancer, including ovarian tissue freezing](https://onco.cc/technologies/rejuv-paed-fertility-female/), [Fertility, growth and what total body irradiation costs](https://onco.cc/technologies/rejuv-tx-fertility-and-growth/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Going back to driving, lifting and exercise](https://onco.cc/technologies/rejuv-rehab-driving-and-exercise-return/), [Going back to work after cancer: the rates, and the programmes that change them](https://onco.cc/technologies/rejuv-life-return-to-work/), [Growth and final height after treatment in childhood, and growth hormone](https://onco.cc/technologies/rejuv-paed-growth-and-height/), [Hearing after platinum and cranial radiotherapy in a developing child](https://onco.cc/technologies/rejuv-paed-hearing/), [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [Heart function after anthracyclines, trastuzumab and chest radiotherapy](https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/), [Hormones, metabolism and the heart after transplant](https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/), [How chronic GvHD is diagnosed and scored: the NIH consensus criteria](https://onco.cc/technologies/gvhd-nih-consensus-criteria/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [How recovery is measured: the questionnaires behind the numbers](https://onco.cc/technologies/rejuv-measure-patient-reported-outcomes/), [Hyperbaric oxygen for late radiation injury](https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/), [Hyperbaric oxygen sold as rejuvenation](https://onco.cc/technologies/rejuv-frontier-hyperbaric-oxygen-claims/), [ICANS, and whether thinking recovers after CAR-T](https://onco.cc/technologies/rejuv-tx-icans-and-neurocognition/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it](https://onco.cc/technologies/rejuv-tx-infection-by-phase/), [Insurance, mortgages and the right to be forgotten](https://onco.cc/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/), [Iron overload after transplant](https://onco.cc/technologies/rejuv-tx-iron-overload/), [Kidneys after cisplatin, ifosfamide, radiotherapy and nephrectomy in childhood](https://onco.cc/technologies/rejuv-paed-kidneys/), [Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked](https://onco.cc/technologies/rejuv-paed-late-mortality/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Living with a stoma, and living after an amputation](https://onco.cc/technologies/rejuv-mind-body-after-stoma-and-limb-loss/), [Long-term follow-up for gene-modified cell products: fifteen years, and why](https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/), [Long-term follow-up in the United Kingdom: what a survivor is actually offered](https://onco.cc/technologies/rejuv-paed-uk-long-term-follow-up/), [Lymphoedema: catching it early, and the operations for it](https://onco.cc/technologies/lymphoedema-surgery-and-early-detection/), [Measuring lymphoedema: tape, bioimpedance and the quality of life scales](https://onco.cc/technologies/rejuv-measure-lymphoedema/), [Measuring memory and concentration after treatment](https://onco.cc/technologies/rejuv-measure-cognitive-function/), [Memory, attention and learning after treatment of a childhood cancer](https://onco.cc/technologies/rejuv-paed-neurocognitive/), [Menopause brought on by cancer treatment, and the options for it](https://onco.cc/technologies/menopause-after-cancer-treatment/), [Mesenchymal stromal cells for tissue damage](https://onco.cc/technologies/rejuv-frontier-mesenchymal-stromal-cells/), [Metformin as an anti-ageing drug after cancer](https://onco.cc/technologies/rejuv-frontier-metformin-ageing/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [NAD+ precursors taken by mouth](https://onco.cc/technologies/rejuv-frontier-nad-precursors/), [Nails after chemotherapy: lifting, ridges and discolouration](https://onco.cc/technologies/nail-changes-after-chemotherapy/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Ovarian function after chemotherapy: who recovers, and when](https://onco.cc/technologies/ovarian-function-after-chemotherapy/), [Partners and relationships after cancer: what the divorce data actually show](https://onco.cc/technologies/rejuv-life-partners-and-intimacy/), [Post-traumatic stress after cancer: what is measured, and how much of it is measurement](https://onco.cc/technologies/rejuv-mind-traumatic-stress-after-cancer/), [Prospective surveillance: looking for the problem before it becomes a disability](https://onco.cc/technologies/rejuv-rehab-prospective-surveillance/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [Quality of life after transplant and cell therapy](https://onco.cc/technologies/rejuv-tx-quality-of-life/), [Rapamycin and mTOR inhibition for ageing](https://onco.cc/technologies/rejuv-frontier-rapamycin-ageing/), [Rebuilding an immune system: the timeline, lineage by lineage](https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/), [Rebuilding the immune system after treatment](https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/), [Recovery after pelvic exenteration](https://onco.cc/technologies/rejuv-recon-pelvic-exenteration/), [Referral to rehabilitation: the service most people who need it never see](https://onco.cc/technologies/rejuv-access-rehabilitation-referral/), [Revaccination after transplant: the schedules, and where the UK and the US differ](https://onco.cc/technologies/rejuv-tx-revaccination/), [Scars, stiffness and contracture: shoulders, necks and jaws](https://onco.cc/technologies/rejuv-rehab-scar-contracture/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/), [Second cancers after childhood cancer: the risk by treatment, and why it is falling](https://onco.cc/technologies/rejuv-paed-second-cancers/), [Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says](https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/), [Senescent cells and p16 after chemotherapy](https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Services built for teenagers and young adults, and what the national evaluation found](https://onco.cc/technologies/rejuv-ayac-services/), [Sexual function and intimacy after cancer, for both sexes](https://onco.cc/technologies/sexual-function-after-cancer/), [Skin during and after radiotherapy: dressings, steroids and what lasts](https://onco.cc/technologies/radiation-skin-recovery/), [Sleep after cancer: how common insomnia is, how long it lasts, and the treatment that works](https://onco.cc/technologies/rejuv-mind-sleep-after-cancer/), [Stem cell clinics and stem cell tourism](https://onco.cc/technologies/rejuv-frontier-stem-cell-tourism/), [Survival after transplant, and why the curve never quite rejoins the population](https://onco.cc/technologies/rejuv-tx-survival-after-transplant/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Swallowing therapy around head and neck radiotherapy](https://onco.cc/technologies/rejuv-rehab-swallowing/), [Teeth, jaws and facial growth after treatment in childhood](https://onco.cc/technologies/rejuv-paed-teeth-and-face/), [Telomere length after treatment](https://onco.cc/technologies/rejuv-age-telomere-length/), [Testosterone after cancer treatment in men](https://onco.cc/technologies/testosterone-after-cancer-treatment/), [The biological age test you can buy, and whether to buy one](https://onco.cc/technologies/rejuv-measure-consumer-biological-age-tests/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The cumulative dose that decides whether it comes back](https://onco.cc/technologies/rejuv-recovery-cumulative-dose/), [The devices that do the restoring, and who pays for them](https://onco.cc/technologies/rejuv-rehab-assistive-devices/), [The exercise prescription after cancer: the dose the guidelines state](https://onco.cc/technologies/exercise-prescription-after-cancer/), [The gap between the rehabilitation people need and the rehabilitation they are offered](https://onco.cc/technologies/rejuv-rehab-provision-gap/), [The handover from children's to adult services, where follow-up falls away](https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/), [The lungs after transplant: bronchiolitis obliterans syndrome](https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/), [The pituitary, puberty and the hypothalamic axis after cranial radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-pituitary-and-puberty/), [The word survivor, and why the vocabulary is not a detail](https://onco.cc/technologies/rejuv-mind-the-word-survivor/), [Thinking and memory after cancer treatment: what is measurable, and what helps](https://onco.cc/technologies/cognitive-impairment-after-cancer-treatment/), [Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees](https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/), [Walking, gripping and standing up: the tests that take five minutes](https://onco.cc/technologies/rejuv-measure-functional-tests/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/), [Where rehabilitation is commissioned, and who misses out](https://onco.cc/technologies/rejuv-rehab-commissioning-inequity/), [Who gets told about fertility before treatment, and who does not](https://onco.cc/technologies/rejuv-access-fertility-preservation/), [Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered](https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/), [Who misses out on recovery care, measured](https://onco.cc/technologies/rejuv-access-who-misses-out/)
- people: [Alexandre Chan](https://onco.cc/people/alexandre-chan/)
- journals: [Pediatric Blood & Cancer](https://onco.cc/journals/pediatric-blood-and-cancer/)
- trials: [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/), [COG ACNS0331](https://onco.cc/trials/acns0331/), [COG AREN0533](https://onco.cc/trials/aren0533/)

---
JSON: https://onco.cc/api/v1/entities/late-effects.json